JAK inhibitors (class)

Medication

What people taking JAK inhibitors (class) report

Every report comes from a Lived member, sent anonymously.

Have you tried JAK inhibitors (class) for Rheumatoid Arthritis?

NameHow it went

About JAK inhibitors (class)

What It's For

JAK inhibitors (Janus kinase inhibitors) are prescription medicines that calm an overactive immune system. Most are tablets or liquids taken by mouth. The best known are tofacitinib (Xeljanz), upadacitinib (Rinvoq) and baricitinib (Olumiant). Their main use is long-term inflammatory disease. All three treat moderate to severe rheumatoid arthritis in adults. Xeljanz and Rinvoq also treat psoriatic arthritis, ankylosing spondylitis (inflammatory arthritis of the spine) and ulcerative colitis, and both are approved for children 2 and older with polyarticular juvenile idiopathic arthritis, a childhood arthritis affecting many joints. Rinvoq is also approved for Crohn's disease, non-radiographic axial spondyloarthritis (spine inflammation that does not yet show on X-ray) and giant cell arteritis, an inflammation of large arteries. For these arthritis and bowel conditions (not giant cell arteritis), US labels generally reserve JAK inhibitors for people whose disease did not respond well to, or who could not tolerate, at least one TNF blocker. TNF blockers are a widely used group of biologic medicines that block tumor necrosis factor, an inflammatory signal. The FDA added this restriction in 2021 after a large safety study, described under Interactions & Warnings. Some JAK inhibitors treat skin and hair conditions. Rinvoq and abrocitinib (Cibinqo) are options for people 12 and older with moderate to severe eczema (atopic dermatitis) that other whole-body treatments, including biologics, have not controlled. Olumiant, for people 12 and older, and deuruxolitinib (Leqselvi), for adults, treat severe alopecia areata, an autoimmune condition that causes patchy or complete hair loss. A cream form of ruxolitinib (Opzelura) is applied to the skin for mild to moderate eczema and for vitiligo, which causes patches of skin to lose color. Olumiant is also used in the hospital for adults with COVID-19 who need oxygen. Ruxolitinib tablets (Jakafi) belong to the same family but treat certain bone marrow disorders and graft-versus-host disease after a stem cell transplant. That setting is different, and this page focuses on JAK inhibitors for immune and inflammatory conditions.

How It Works

Immune reactions are coordinated by cytokines, messenger proteins that immune cells release to recruit more inflammation. When a cytokine attaches to a receptor on the outside of a cell, enzymes called Janus kinases (JAKs) carry the message inward and switch on genes involved in inflammation and immune activity. In conditions such as rheumatoid arthritis or ulcerative colitis, this signaling stays active and drives ongoing pain, swelling and tissue damage. JAK inhibitors block these enzymes from inside the cell. Because many different cytokines rely on JAKs, one medicine can quiet several inflammatory signals at once, rather than blocking a single target the way a TNF blocker does. That breadth helps explain both their effect and their main trade-off: some of the same signals help the body fight infection, so dampening them raises infection risk. Individual JAK inhibitors favor different JAK enzymes, but how much that changes benefit or safety is not known.

Dosage & Administration

The tablets and liquids are taken by mouth once or twice a day; Opzelura cream is applied to the skin. The dose depends on the specific medicine, the condition being treated, and factors such as kidney or liver function and other medicines. Xeljanz is a twice-daily tablet, Xeljanz XR is a once-daily extended-release tablet, and a liquid form is used for children. Rinvoq is a once-daily extended-release tablet that must be swallowed whole, not split, crushed or chewed; its liquid form, Rinvoq LQ, is dosed differently and should not be swapped for the tablets without the prescriber. Olumiant is a once-daily tablet. Rinvoq and Olumiant can be taken with or without food. For ulcerative colitis and Crohn's disease, treatment usually starts with a higher induction dose for 8 to 12 weeks to bring inflammation under control, then steps down to a lower maintenance dose. For most conditions the aim is the lowest dose that keeps the disease controlled, because higher doses carry a greater risk of serious infection. Doses are not interchangeable between different JAK inhibitors or between forms of the same one.

Side Effects

The most common side effects are colds and other upper respiratory infections, headache, diarrhea and nausea. Acne is common with Rinvoq and with Olumiant for alopecia areata, and cold sores (herpes simplex) can flare. Blood tests can show higher cholesterol or changes in blood counts or liver enzymes, usually without symptoms, which is one reason for regular lab checks. Shingles (herpes zoster), a painful blistering rash caused by reactivation of the chickenpox virus, occurs more often than with TNF blockers. A new painful rash, especially a band of blisters on one side of the body, is worth reporting promptly. Because these medicines weaken some immune defenses, infections can become serious. Pneumonia and skin infections are the most frequent, and less common ones such as tuberculosis or fungal infections can occur. Call the care team right away for signs of infection, such as fever, sweating or chills, cough or shortness of breath, warm, red or painful skin, or burning when urinating. Rarely, a tear develops in the stomach or intestines, more often in people with diverticulitis or those also taking corticosteroids or anti-inflammatory painkillers such as ibuprofen. Fever with stomach pain that does not go away and a change in bowel habits needs a call to the care team right away. Serious allergic reactions can also occur. Swelling of the lips, tongue or throat, trouble breathing, or feeling faint or dizzy, with or without hives, means stop the medicine and get emergency help right away. Hives on their own (raised, itchy welts, often widespread, unlike the one-sided band of shingles or acne) call for contacting the care team the same day before taking another dose.

Interactions & Warnings

Xeljanz, Rinvoq, Olumiant, Cibinqo, Leqselvi and Opzelura cream carry the FDA's boxed warning, its most prominent caution, for serious infections, death, cancer, major heart problems and blood clots. It comes from a large trial in adults with rheumatoid arthritis who were 50 or older and had at least one heart risk factor. Compared with a TNF blocker, tofacitinib (Xeljanz) led to higher rates of heart attack and stroke, blood clots in the lungs and veins, lymphoma and lung cancer, and death. Current or past smokers had additional cancer risk. The other JAK inhibitors were not tested in a trial like this, but because they work the same way, the FDA treats them as possibly carrying similar risks. Large observational studies comparing JAK inhibitors with TNF blockers in everyday practice found no clear difference for most of these outcomes apart from a slightly higher rate of blood clots, so the size of the risk is still debated. Prescribers weigh it most carefully in people who smoke or used to, have other heart risk factors, or have had cancer. Tell the prescriber if you smoke or used to, or have had a heart attack, other heart problems, a stroke or blood clots. Get emergency help right away for symptoms that may signal a heart attack, stroke or blood clot: chest pain, pressure or tightness; shortness of breath; weakness on one side of the body, slurred speech or a drooping face; or a swollen, painful or discolored leg or arm. Report swollen lymph nodes, night sweats, a persistent or worsening cough or unexplained weight loss, which can be signs of lymphoma or lung cancer. JAK inhibitors are not meant to be combined with biologic medicines, other JAK inhibitors, or strong immune-suppressing drugs such as azathioprine and cyclosporine, because the immune suppression adds up. In rheumatoid arthritis they can be used with methotrexate, a standard first-line arthritis medicine. Some medicines change blood levels: rifampin, an antibiotic used for tuberculosis, can lower Xeljanz and Rinvoq levels enough to weaken them, while the antifungal ketoconazole and the antibiotic clarithromycin can raise them. Grapefruit should be avoided with Rinvoq. Probenecid, a gout medicine, raises Olumiant levels and calls for a lower dose. Live vaccines should be avoided during treatment, so it helps to bring vaccinations up to date before starting. Animal studies suggest these medicines may harm a developing baby, and human data are limited; Rinvoq's label advises effective contraception during treatment and for 4 weeks after the last dose for anyone who could become pregnant. Breastfeeding is not recommended during treatment and for a set time after the last dose; the interval differs by medicine, and the prescriber or pharmacist can give the exact one. Anyone pregnant or planning pregnancy should discuss timing with the prescriber.

What to Expect

Before starting, people are tested for tuberculosis, including the dormant (latent) form, which is treated first if found, and screened for viral hepatitis such as hepatitis B. Baseline blood counts and liver tests are checked. During treatment, blood counts, liver enzymes and cholesterol are rechecked periodically, and the care team keeps watching for tuberculosis even after a negative test, because the medicine can let a hidden infection become active. How quickly benefit appears depends on the condition. In a large rheumatoid arthritis trial of tofacitinib (Xeljanz), improvement was seen from the second month and lasted through about four years of follow-up. For ulcerative colitis and Crohn's disease, the team judges response at the end of the higher starting dose and moves to maintenance, or considers other options if the benefit is not adequate. Hair regrowth in alopecia areata is slower: the main trials judged regrowth after about six to nine months (24 weeks for Leqselvi, 36 weeks for Olumiant). Treatment is usually long term, using the lowest dose that keeps the condition under control. The medicine is usually paused during a serious infection or an episode of shingles and restarted once it is controlled. Apart from the emergency allergy signs under Side Effects, ask the care team before stopping or pausing it.

Questions to Ask Your Doctor

  1. 1.Why is a JAK inhibitor the right next step for me, given my past treatments, smoking history and heart and cancer risk?
  2. 2.Which JAK inhibitor and dose do you recommend, and by when should we know whether it is working?
  3. 3.Which tests do I need before starting, and how often will my blood work be checked?
  4. 4.Which vaccines should I get before starting, and what should I do if I get a fever or a shingles rash?
  5. 5.How does this medicine fit with my other medicines and any plans for pregnancy or breastfeeding?

Last reviewed • Oct 2026

Educational content, not medical advice.